A Phase 1 interventional study of Imlunestrant and Repaglinide in Healthy, sponsored by Eli Lilly and Company. Completed at 3 sites in United States. Open to female participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-12.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to evaluate the effect of imlunestrant on repaglinide, omeprazole and dextromethorphan, and rosuvastatin and digoxin. The study will also investigate the effect of quinidine on imlunestrant in female healthy participants of non-childbearing potential. The safety and tolerability of imlunestrant will be investigated in female healthy participants of non-childbearing potential. The study will last approximately up to 32 days for each participant excluding the screening period.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received: Day 1: A single oral dose of 0.5 mg repaglinide administered alone. Day 3: A single oral dose of 800 mg imlunestrant, followed approximately 2 hours later by 0.5 mg repaglinide, both administered orally.
Drug: Imlunestrant · Drug: Repaglinide
Participants received: Day 1: A single oral dose of 20 mg omeprazole and 30 mg dextromethorphan, administered in the morning. Day 3: A single oral dose of 800 mg imlunestrant, followed immediately by 20 mg omeprazole and 30 mg dextromethorphan, all administered orally.
Drug: Imlunestrant · Drug: Omeprazole · Drug: Dextromethorphan
Participants received: Day 1: A single oral dose of 400 mg imlunestrant, administered in the morning. Days 15 to 17 and 19 to 24: Twice-daily oral doses of 200 mg quinidine, administered alone. Day 18: A single oral dose of 400 mg imlunestrant administered in combination with 200 mg quinidine (quinidine was dosed twice on this day as part of the regular regimen).
Drug: Imlunestrant · Drug: Quinidine
Participants received: Day 1: A single oral dose of 10 mg rosuvastatin and 0.25 mg digoxin, administered in the morning. Day 10: A single oral dose of 400 mg imlunestrant, administered in combination with 10 mg rosuvastatin and 0.25 mg digoxin, all administered orally.
Drug: Imlunestrant · Drug: Rosuvastatin · Drug: Digoxin
Administered orally.
Also known as: LY3484356
Administered orally.
Administered orally.
Administered orally.
Administered orally.
Administered orally.
Administered orally.
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Repaglinide (Cohort 1)
PK: AUC\[0-∞\] of Repaglinide
Time frame: Day 1 and Day 3: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose
PK: Maximum Observed Concentration (Cmax) of Repaglinide (Cohort 1)
PK: Cmax of Repaglinide
Time frame: Day 1 and Day 3: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose
PK: AUC[0-∞] of Omeprazole (Cohort 2)
PK: AUC\[0-∞\] of Omeprazole
Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8,12, and 24 h postdose; Day 3: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, and 48 h postdose
PK: Cmax of Omeprazole (Cohort 2)
PK: Cmax of Omeprazole
Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8,12, and 24 h postdose; Day 3: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, and 48 h postdose
PK: AUC[0-∞] of Omeprazole Metabolite: 5-hydroxyomeprazole (Cohort 2)
5-hydroxyomeprazole is a major metabolite of omeprazole.
Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8,12, and 24 h postdose; Day 3: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, and 48 h postdose
PK: Cmax of Omeprazole Metabolite: 5-hydroxyomeprazole (Cohort 2)
5-hydroxyomeprazole is a major metabolite of omeprazole.
Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8,12, and 24 h postdose; Day 3: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, and 48 h postdose
PK: AUC[0-∞] of Dextromethorphan (Cohort 2)
PK: AUC\[0-∞\] of Dextromethorphan
Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8,12, and 24 h postdose; Day 3: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, and 48 h postdose
PK: Cmax of Dextromethorphan (Cohort 2)
PK: Cmax of Dextromethorphan
Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8,12, and 24 h postdose; Day 3: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, and 48 h postdose
PK: Area Under the Concentration Versus Time Curve (AUC) From Time Zero to Tlast (AUC[0-tlast]) of Dextromethorphan Metabolite: Dextrorphan (Cohort 2)
Dextrorphan is a major metabolite of Dextromethorphan.
Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8,12, and 24 h postdose; Day 3: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, and 48 h postdose
PK: Cmax of Dextromethorphan Metabolite: Dextrorphan (Cohort 2)
Dextrorphan is a major metabolite of Dextromethorphan.
Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8,12, and 24 h postdose; Day 3: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, and 48 h postdose
PK: AUC[0-∞] of Imlunestrant (Cohort 3)
PK: AUC\[0-∞\] of Imlunestrant
Time frame: Day 1 and Day 18: Predose, 1, 2, 3, 4, 5, 6 ,8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 h post dose
PK: Cmax of Imlunestrant (Cohort 3)
PK: Cmax of Imlunestrant
Time frame: Day 1 and Day 18: Predose, 1, 2, 3, 4, 5, 6 ,8, 12, 24, 36, 48, 72, 96, 120, 144, and 168 h post dose
PK: AUC[0-∞] of Rosuvastatin (Cohort 4)
PK: AUC\[0-∞\] of Rosuvastatin
Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, and 96 h post dose; Day 10: Predose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, and 120 h post dose
PK: Cmax of Rosuvastatin (Cohort 4)
PK: Cmax of Rosuvastatin
Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, and 96 h post dose; Day 10: Predose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, and 120 h post dose
PK: AUC[0-∞] of Digoxin (Cohort 4)
PK: AUC\[0-∞\] of Digoxin
Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, and 96 h post dose; Day 10: Predose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, and 120 h post dose
PK: Cmax of Digoxin (Cohort 4)
PK: Cmax of Digoxin
Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, and 96 h post dose; Day 10: Predose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, and 120 h post dose
| Milestone | Imlunestrant + Repaglinide (Cohort 1) | Imlunestrant + Omeprazole & Dextromethorphan (Cohort 2) | Imlunestrant + Quinidine (Cohort 3) | Imlunestrant + Rosuvastatin & Digoxin (Cohort 4) |
|---|---|---|---|---|
| Started | 27 | 27 | 32 | 27 |
| Received at least one dose of study drug | 27 | 27 | 32 | 27 |
| Completed | 27 | 27 | 30 | 26 |
| Not completed | 0 | 0 | 2 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 2 | 1 |
PK: AUC\[0-∞\] of Repaglinide
| nanogram*hour per milliliter (ng*hr/mL) | 0.5 mg Repaglinide | 800 mg Imlunestrant + 0.5 mg Repaglinide |
|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Repaglinide (Cohort 1) | 13.0 ± 31 | 13.6 ± 31 |
PK: Cmax of Repaglinide
| nanogram per millilitre (ng/mL) | 0.5 mg Repaglinide | 800 mg Imlunestrant + 0.5 mg Repaglinide |
|---|---|---|
| PK: Maximum Observed Concentration (Cmax) of Repaglinide (Cohort 1) | 10.5 ± 38 | 9.84 ± 44 |
PK: AUC\[0-∞\] of Omeprazole
| ng*hr/mL | 20 mg Omeprazole + 30 mg Dextromethorphan | 800 mg Imlunestrant + 20 mg Omeprazole + 30 mg Dextromethorphan |
|---|---|---|
| PK: AUC[0-∞] of Omeprazole (Cohort 2) | 703 ± 77 | 825 ± 74 |
PK: Cmax of Omeprazole
| ng/mL | 20 mg Omeprazole + 30 mg Dextromethorphan | 800 mg Imlunestrant + 20 mg Omeprazole + 30 mg Dextromethorphan |
|---|---|---|
| PK: Cmax of Omeprazole (Cohort 2) | 316 ± 73 | 405 ± 57 |
5-hydroxyomeprazole is a major metabolite of omeprazole.
| ng*hr/mL | 20 mg Omeprazole + 30 mg Dextromethorphan | 800 mg Imlunestrant + 20 mg Omeprazole + 30 mg Dextromethorphan |
|---|---|---|
| PK: AUC[0-∞] of Omeprazole Metabolite: 5-hydroxyomeprazole (Cohort 2) | 571 ± 26 | 592 ± 19 |
5-hydroxyomeprazole is a major metabolite of omeprazole.
| ng/mL | 20 mg Omeprazole + 30 mg Dextromethorphan | 800 mg Imlunestrant + 20 mg Omeprazole + 30 mg Dextromethorphan |
|---|---|---|
| PK: Cmax of Omeprazole Metabolite: 5-hydroxyomeprazole (Cohort 2) | 200 ± 52 | 230 ± 42 |
PK: AUC\[0-∞\] of Dextromethorphan
| ng*hr/mL | 20 mg Omeprazole + 30 mg Dextromethorphan | 800 mg Imlunestrant + 20 mg Omeprazole + 30 mg Dextromethorphan |
|---|---|---|
| PK: AUC[0-∞] of Dextromethorphan (Cohort 2) | 14.7 ± 127 | 16.1 ± 111 |
PK: Cmax of Dextromethorphan
| ng/mL | 20 mg Omeprazole + 30 mg Dextromethorphan | 800 mg Imlunestrant + 20 mg Omeprazole + 30 mg Dextromethorphan |
|---|---|---|
| PK: Cmax of Dextromethorphan (Cohort 2) | 0.864 ± 124 | 1.13 ± 124 |
Dextrorphan is a major metabolite of Dextromethorphan.
| ng*hr/mL | 20 mg Omeprazole + 30 mg Dextromethorphan | 800 mg Imlunestrant + 20 mg Omeprazole + 30 mg Dextromethorphan |
|---|---|---|
| PK: Area Under the Concentration Versus Time Curve (AUC) From Time Zero to Tlast (AUC[0-tlast]) of Dextromethorphan Metabolite: Dextrorphan (Cohort 2) | 11.8 ± 62 | 11.9 ± 75 |
Dextrorphan is a major metabolite of Dextromethorphan.
| ng/mL | 20 mg Omeprazole + 30 mg Dextromethorphan | 800 mg Imlunestrant + 20 mg Omeprazole + 30 mg Dextromethorphan |
|---|---|---|
| PK: Cmax of Dextromethorphan Metabolite: Dextrorphan (Cohort 2) | 1.79 ± 50 | 1.97 ± 56 |
PK: AUC\[0-∞\] of Imlunestrant
| ng*hr/mL | 400 mg Imlunestrant (Day 1) | 400 mg Imlunestrant + 200 mg Quinidine BID (Day 18) |
|---|---|---|
| PK: AUC[0-∞] of Imlunestrant (Cohort 3) | 1970 ± 66 | 1870 ± 87 |
PK: Cmax of Imlunestrant
| ng/mL | 400 mg Imlunestrant (Day 1) | 400 mg Imlunestrant + 200 mg Quinidine BID (Day 18) |
|---|---|---|
| PK: Cmax of Imlunestrant (Cohort 3) | 61.0 ± 82 | 54.3 ± 81 |
PK: AUC\[0-∞\] of Rosuvastatin
| ng*hr/mL | 10 mg Rosuvastatin + 0.25 mg Digoxin | 400 mg Imlunestrant + 10 mg Rosuvastatin + 0.25 mg Digoxin |
|---|---|---|
| PK: AUC[0-∞] of Rosuvastatin (Cohort 4) | 29.0 ± 47 | 44.9 ± 51 |
PK: Cmax of Rosuvastatin
| ng/mL | 10 mg Rosuvastatin + 0.25 mg Digoxin | 400 mg Imlunestrant + 10 mg Rosuvastatin + 0.25 mg Digoxin |
|---|---|---|
| PK: Cmax of Rosuvastatin (Cohort 4) | 2.99 ± 53 | 5.08 ± 59 |
PK: AUC\[0-∞\] of Digoxin
| ng*hr/mL | 10 mg Rosuvastatin + 0.25 mg Digoxin | 400 mg Imlunestrant + 10 mg Rosuvastatin + 0.25 mg Digoxin |
|---|---|---|
| PK: AUC[0-∞] of Digoxin (Cohort 4) | 20.2 ± 23 | 28.0 ± 19 |
PK: Cmax of Digoxin
| ng/mL | 10 mg Rosuvastatin + 0.25 mg Digoxin | 400 mg Imlunestrant + 10 mg Rosuvastatin + 0.25 mg Digoxin |
|---|---|---|
| PK: Cmax of Digoxin (Cohort 4) | 1.17 ± 39 | 1.88 ± 38 |
Collected over Cohort 1: up to 11 days, Cohort 2: up to 12 days, Cohort 3: up to 32 days, Cohort 4: up to 22 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 0.5 mg Repaglinide: Cohort 1 | 0/27 (0%) | 0/27 (0%) | 2/27 (7.4%) |
| 800 mg Imlunestrant + 0.5 mg Repaglinide: Cohort 1 | 0/27 (0%) | 0/27 (0%) | 0/27 (0%) |
| 20 mg Omeprazole + 30 mg Dextromethorphan: Cohort 2 | 0/27 (0%) | 0/27 (0%) | 3/27 (11.1%) |
| 800 mg Imlunestrant + 20 mg Omeprazole + 30 mg Dextromethorphan: Cohort 2 | 0/27 (0%) | 0/27 (0%) | 3/27 (11.1%) |
| 400 mg Imlunestrant (Day 1): Cohort 3 | 0/32 (0%) | 0/32 (0%) | 9/32 (28.1%) |
| 200 mg Quinidine BID (Days 15 to 17): Cohort 3 | 0/32 (0%) | 0/32 (0%) | 3/32 (9.4%) |
| 400 mg Imlunestrant + 200 mg Quinidine BID (Day 18): Cohort 3 | 0/31 (0%) | 0/31 (0%) | 0/31 (0%) |
| 200 mg Quinidine BID (Days 19 to 24): Cohort 3 | 0/31 (0%) | 0/31 (0%) | 4/31 (12.9%) |
| 10 mg Rosuvastatin + 0.25 mg Digoxin: Cohort 4 | 0/27 (0%) | 0/27 (0%) | 0/27 (0%) |
| 400 mg Imlunestrant + 10 mg Rosuvastatin + 0.25 mg Digoxin: Cohort 4 | 0/26 (0%) | 0/26 (0%) | 1/26 (3.8%) |
| Event | 0.5 mg Repaglinide: Cohort 1 | 800 mg Imlunestrant + 0.5 mg Repaglinide: Cohort 1 | 20 mg Omeprazole + 30 mg Dextromethorphan: Cohort 2 | 800 mg Imlunestrant + 20 mg Omeprazole + 30 mg Dextromethorphan: Cohort 2 | 400 mg Imlunestrant (Day 1): Cohort 3 | 200 mg Quinidine BID (Days 15 to 17): Cohort 3 | 400 mg Imlunestrant + 200 mg Quinidine BID (Day 18): Cohort 3 | 200 mg Quinidine BID (Days 19 to 24): Cohort 3 | 10 mg Rosuvastatin + 0.25 mg Digoxin: Cohort 4 | 400 mg Imlunestrant + 10 mg Rosuvastatin + 0.25 mg Digoxin: Cohort 4 |
|---|---|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 1/27 | 0/27 | 3/27 | 1/27 | 4/32 | 1/32 | 0/31 | 2/31 | 0/27 | 1/26 |
| ConstipationGastrointestinal disorders | 0/27 | 0/27 | 0/27 | 1/27 | 3/32 | 0/32 | 0/31 | 0/31 | 0/27 | 0/26 |
| DiarrhoeaGastrointestinal disorders | 0/27 | 0/27 | 0/27 | 2/27 | 0/32 | 1/32 | 0/31 | 2/31 | 0/27 | 0/26 |
| NauseaGastrointestinal disorders | 1/27 | 0/27 | 0/27 | 0/27 | 0/32 | 2/32 | 0/31 | 0/31 | 0/27 | 0/26 |
| Back painMusculoskeletal and connective tissue disorders | 0/27 | 0/27 | 0/27 | 0/27 | 2/32 | 0/32 | 0/31 | 0/31 | 0/27 | 0/26 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/27 | 0/27 | 0/27 | 0/27 | 2/32 | 0/32 | 0/31 | 0/31 | 0/27 | 0/26 |
All enrolled participants.
| Age, Continuous(years) | Imlunestrant + Repaglinide (Cohort 1) | Imlunestrant + Omeprazole & Dextromethorphan (Cohort 2) | Imlunestrant + Quinidine (Cohort 3) | Imlunestrant + Rosuvastatin & Digoxin (Cohort 4) | Total |
|---|---|---|---|---|---|
| Mean | 53.3 ± 8.2 | 52.6 ± 8.2 | 55.9 ± 6.3 | 54.1 ± 7.1 | 54.1 ± 7.4 |
| Sex: Female, Male(Participants) | Imlunestrant + Repaglinide (Cohort 1) | Imlunestrant + Omeprazole & Dextromethorphan (Cohort 2) | Imlunestrant + Quinidine (Cohort 3) | Imlunestrant + Rosuvastatin & Digoxin (Cohort 4) | Total |
|---|---|---|---|---|---|
| Female | 27 | 27 | 32 | 27 | 113 |
| Male | 0 | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Imlunestrant + Repaglinide (Cohort 1) | Imlunestrant + Omeprazole & Dextromethorphan (Cohort 2) | Imlunestrant + Quinidine (Cohort 3) | Imlunestrant + Rosuvastatin & Digoxin (Cohort 4) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 22 | 19 | 23 | 14 | 78 |
| Not Hispanic or Latino | 5 | 8 | 9 | 13 | 35 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Imlunestrant + Repaglinide (Cohort 1) | Imlunestrant + Omeprazole & Dextromethorphan (Cohort 2) | Imlunestrant + Quinidine (Cohort 3) | Imlunestrant + Rosuvastatin & Digoxin (Cohort 4) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 1 | 0 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 5 | 4 | 7 | 19 |
| White | 23 | 21 | 27 | 19 | 90 |
| More than one race | 0 | 0 | 1 | 1 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Imlunestrant + Repaglinide (Cohort 1) | Imlunestrant + Omeprazole & Dextromethorphan (Cohort 2) | Imlunestrant + Quinidine (Cohort 3) | Imlunestrant + Rosuvastatin & Digoxin (Cohort 4) | Total |
|---|---|---|---|---|---|
| United States | 27 | 27 | 32 | 27 | 113 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2022 to primary completion in Nov 2022, 3 months.
Results were first posted in Dec 2025, 3 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Imlunestrant